These findings imply that targeting PDGFB signaling pathway may inhibit angiogenesis via blocking TECs to recruit pericytes and repressing the pericyte-myofibroblast transition51,64,65, which offers a new therapeutic option for cancer treatment. The gene discussed is PDGFB; the disease is cancer.